CClinicalTrials.gg
CompletedNCT05373459Updated Feb 28, 2024

Effect of a Third COVID-19 Booster Among Health Care Workers

An observational study in COVID-19 Vaccines, sponsored by Hong Kong Sanatorium & Hospital. Completed at 1 site in Hong Kong. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by Hong Kong Sanatorium & Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
3,167
Ages
18 Years and older
Sex
All
01

Study summary

A new wave of COVID-19 infections, mainly caused by the Omicron/ Delta variant, has been sweeping the globe since the start of 2022. In response, the administration of a third dose of COVID-19 vaccine was considered to address potential waning immunity over time and reduced effectiveness against the Omicron/ Delta variant. The pandemic also resulted in many infections among health care workers (HCWs) and their households. In this study, a retrospective analysis would perform on risk of COVID-19 infection and their outcome in relation to their COVID-19 vaccination history by using the data repository from one of the Hong Kong private hospitals.

HCWs were required to submit a standardized online self-declaration form for report of 1) demographic of the HCWs, 2) symptoms related history and 3) COVID-19 exposure history once they were COVID-19 confirmed by rapid antigen test against COVID-19 and/or polymerase chain reaction (PCR) test for COVID-19. Subsequent follow up such as contact tracing, COVID-19 PCR testing results of these HCWs and status of return to work were captured by the infection control team in a systematic manner.

02

Conditions studied

  • COVID-19 Vaccines

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

All full time staff members of the private hospital

Inclusion criteria

  • All full time staff members of the private hospital

Exclusion criteria

Exclusion Criteria:

  • History of COVID-19 before 2022
04

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
3,167 participants (actual)
Patient registry
No

Groups and cohorts

  • Health care workers without third COVID-19 booster

    Health care workers received less than 3 doses of COVID-19 vaccine

  • HCWs with third COVID-19 booster

    Health care workers received at least 3 doses of COVID-19 vaccine

    Biological: Third COVID-19 booster

Interventions

  • BiologicalThird COVID-19 booster

    Third COVID-19 booster

05

What researchers measure

Primary outcomes

  1. COVID-19 Infection

    Number of participants with COVID-19 infected

    Time frame: During 1 February - 31 March 2022

  2. Number of days return to work after COVID-19 infection

    Number of days return to work after COVID-19 infection

    Time frame: During 1 February - 31 March 2022

06

Study locations

1 site
  • Hong Kong Sanatorium & Hospital
    Hong Kong, Hong Kong
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05373459
Lead sponsor
Hong Kong Sanatorium & Hospital
Responsible party
Dr. Jonpaul ST Zee (Specialist in Infectious Disease, Hong Kong Sanatorium & Hospital) — Principal investigator
First posted
May 13, 2022
Start date
May 16, 2022
Primary completion
Dec 31, 2022
Completion
Dec 31, 2022
Last update
Feb 28, 2024

Study contacts

Jonpaul Sze Tsing Zee, MBChB
principal investigator · Hong Kong Sanatorium & Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion